Key result
Post-ACS omega-3 EPA eligibility reaches ~32% at one year, dropping with systematic lipid lowering.
Why the study?
What proportion of patients with acute coronary syndromes are eligible for marine omega-3 FA-EPA supplementation based on triglyceride levels?
Cohort (n=2,643)
What proportion of patients with acute coronary syndromes are eligible for marine omega-3 FA-EPA supplementation based on triglyceride levels?
Answers are grounded in this paper and cite their sources.
Up to 32% of patients with ACS in a contemporary cohort are eligible for omega-3 FA-EPA supplementation one year post-event, representing a significant opportunity to address residual cardiovascular risk.
Background and aims: The 2019 European Society of Cardiology guidelines for the management of dyslipidemia consider the use of high-dose marine omega-3 fatty acid (FA) eicosapentaenoic acid (EPA) supplementation (icosapent ethyl 2 × 2g/day) to lower residual cardiovascular risk in high-risk patients with hypertriglyceridemia. This study aimed to assess the eligibility for omega-3 FA-EPA supplementation in patients with acute coronary syndromes (ACS). Methods: In a prospective Swiss cohort of patients hospitalized for ACS, eligibility for marine omega-3 FA-EPA, defined as plasma triglyceride levels ranging from 1.5 to 5.6 mmol/l, was assessed at baseline and one-year follow-up and compared across subgroups. Lipid-lowering therapy intensification with statin and ezetimibe was modelled to simulate a hypothetical systematic treatment and its effect on omega-3 FA-EPA supplementation eligibility. Results: Of 2643 patients, 98 % were prescribed statin therapy at discharge, including 62 % at a high-intensity regimen; 93 % maintained it after one year, including 53 % at a high-intensity regimen. The use of ezetimibe was 3 % at discharge and 7 % at one year. Eligibility was observed in 32 % (32 % men, 29 % women) one year post-ACS. After modelling systematic treatment with statins, ezetimibe, and both, eligibility decreased to 31 %, 25 % and 24 %, respectively. Eligibility was higher in individuals aged <70 (34 vs 25 %), smokers (38 vs 28 %), diabetics (46 vs 29 %), hypertensive (35 vs 29 %), and obese patients (46 vs 22 % for normal weight), all with p-values <0.001. Conclusion: In a contemporary Swiss cohort of patients with ACS, up to 32 % would be eligible for omega-3 FA-EPA supplementation one year after ACS, highlighting an opportunity to mitigate residual cardiovascular risk in patients with ACS and hypertriglyceridemia.
No takes yet. Share an insight, caveat, or question.
Follonier et al. (2024) conducted a cohort in Acute coronary syndromes (n=2,643). Eligibility for marine omega-3 FA-EPA supplementation was evaluated on Eligibility for marine omega-3 FA-EPA supplementation (plasma triglyceride levels 1.5 to 5.6 mmol/l) at one year. One year after acute coronary syndromes, 32% of patients in a Swiss cohort were eligible for omega-3 FA-EPA supplementation, decreasing to 24% after modelling systematic lipid-lowering therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: